on this page
Patient eligibility
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with eculizumab or ravulizumab under the National Health Act 1953, section 100 for patients with paroxysmal nocturnal haemoglobinuria (PNH). Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing eculizumab or ravulizumab.
Section 100 arrangements
eculizumab or ravulizumab
These items are only PBS subsidised for day admitted patients, non-admitted patients, or patients on discharge who are attending either:
- an approved private hospital
- a public participating hospital
- a public hospital.
These items aren’t PBS subsidised for hospital in-patients. You must include the hospital name and provider number on the authority application form.
Treatment specifics
To be eligible for PBS subsidised treatment with eculizumab or ravulizumab, patients must be treated by a haematologist or by a non-specialist medical practitioner in consultation with a haematologist.
Authority applications
Applying for initial treatment, switching due to pregnancy or balance of supply
Apply for initial, switching due to pregnancy or balance of supply authority approval to prescribe PBS subsidised eculizumab or ravulizumab to treat paroxysmal nocturnal haemoglobinuria in writing and either:
- upload through Health Professional Online Services (HPOS)
- post to PBS Complex Drugs Programs.
All written applications must include the completed:
- authority prescription form or forms
- paroxysmal nocturnal haemoglobinuria - eculizumab or ravulizumab - initial, switching due to pregnancy or balance of supply authority application form
- relevant attachments.
Applying for initial grandfather treatment
Patients who received non-PBS subsidised eculizumab or ravulizumab treatment before 1 March 2022 for paroxysmal nocturnal haemoglobinuria can apply for initial grandfather authority approval in writing and either:
- upload through HPOS
- post to PBS Complex Drugs Programs.
All written applications must include the completed:
- authority prescription form or forms
- paroxysmal nocturnal haemoglobinuria - eculizumab or ravulizumab - initial grandfather authority application form
- relevant attachments.
Applying for continuing treatment
Apply for continuing authority approval to prescribe PBS subsidised eculizumab or ravulizumab to treat paroxysmal nocturnal haemoglobinuria in writing and either:
- upload through HPOS
- post to PBS Complex Drugs Programs.
All applications must include the completed:
- authority prescription form or forms
- paroxysmal nocturnal haemoglobinuria - eculizumab or ravulizumab continuing authority application form
- relevant attachments.
More information
Call the PBS Complex Drugs Programs enquiry line for more information.